Quebec might not seem like the obvious place to get into the cannabis business. For the few cannabis businesses calling Quebec their home however, there is major upside and potential in doing business in French Canada.

The Canadian market spent $5.7 billion on cannabis in 2017, and, according to Marijuana Business Daily, Quebec’s recreational cannabis market could well grow to become the second largest in Canada, mirroring its status as the second most populous province. The Parliamentary Budget Office estimates that the province could consume as much as 200,000 kilograms of cannabis next year. That ties together with a potential for annual recreational sales of around $150 million in Quebec in 2019.


Because Quebec is warming to the cannabis industry at slower pace than the rest of Canada, many businesses are skeptical about the idea of operating in the province. Public opinion in Quebec is the least friendly to cannabis in the country and as a reflection of that sentiment, the regulatory framework laid out by the provincial government is among the most restrictive in the Canada. The upside to this, however, is a provincial cannabis industry that is far less crowded than the rest of the country

As of now, Quebec has a very small pool of licensed growers and the smallest rate of license applications in the country. This means that there are only a few players around to take advantage of a massive and barely tapped market.

Cannabis in Quebec

As with the other provinces, the Quebec government is responsible for regulating and enforcing the production of cannabis as well as laying out health and safety regulations and restrictions. The provincial government unveiled its plans for regulation in November of last year and has decided that the Société des alcools du Québec, the same organization through which liquor is sold in the province, will oversee the sale of cannabis. Cannabis sales will be limited exclusively to 20 government-run stores. Growing at home is strictly forbidden in the province. As is any form of unlicensed cultivation, whether for personal or commercial use.

However, tough regulations are only one part of the story for cannabis businesses in Quebec.

Hydro Quebec provides companies with the least expensive energy in Canada. Additionally, since Quebec has 20 percent of the country’s population and only a few of the licensed cannabis producers, there is a strong pool of land, labor and technical expertise available for low cost in comparison to the rest of the country.

Since the Quebec provincial government will be supporting the retail outlets where cannabis is sold, it is likely that the government will prefer to source their product from local growers, putting local producers in a potentially enviable situation.

Another benefit for cannabis companies in Quebec is the province’s post-secondary institutions, who are eager to be involved in clinical studies and research, according to Rob Gietl, CEO of Canadian cannabis producer MYM Nutraceuticals (CSE:MYM). MYM will be opening two large growing facilities in Weedon and Laval Quebec and operate distribution and nutraceuticals manufacturing throughout Canada. Gietl says this eagerness on the part of post-secondary institutions will create a “syndicate of experts” that will help companies like MYM develop intellectual property that can be shared globally.

Still, there’s a cultural aspect that cannabis producers must contend with. In regards to public opinion, Quebec is the least enthusiastic province in the country about cannabis legalization. According to a report released by the government of Quebec last year, 60 percent of survey respondents were worried about consequences of legalization, though 57 percent of those respondents were overall in favor of legalization.

According to Gietl, data like this speaks to a need for outreach on the part of cannabis producers to encourage engagement with the communities in which they do business. To that end, MYM has launched an awareness campaign, asking users to visit www.cannafacts.ca to “initiate a conversation with Canadians.”

Quebec’s cannabis industry players

Currently there are six cannabis producers licensed to operate in Quebec; Agri-Médic ASP, Agro-Biotech, Aurora Cannabis Enterprises (TSX:ACB,OTCQB:ACBFF,FWB:21P), Hydropothecary (TSX:THCX), IsoCanMed, and Vert Cannabis. The province announced these first licensed producers in February of 2018.

Though not yet licensed in Quebec, MYM and its subsidiaries are deep in the process of acquiring licensed producer status. The company has big plans for Quebec. They’ve entered into a partnership with the municipality of Weedon, Quebec to build a 1.5 million-square-foot greenhouse facility in the town, capable of producing 150 metric tons of cannabis per year. In addition to serving as a growing center, the facility will serve as a space for research and development of cannabis products.

The Weedon facility will also serve as a means for community outreach. The facility is going to include such amenities as a cannabis museum, research facilities, an auditorium, and more. This is part of the company’s effort to get the local community engaged with the industry.

Takeaway

Quebec has been written off by some as too hostile to the cannabis business. Companies have been slow to move into the province, but it’s precisely because of this that Quebec presents such an interesting opportunity for cannabis producers. A market of over eight million people with only a handful of companies moving in to serve the province coupled with low hydro costs and relatively inexpensive talent suggests that Quebec could be a remarkably good opportunity for the few cannabis producers willing to move in on the underserved market.

This INNspired article  was written according to INN editorial standards to educate investors.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less